Lantheus Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantheus Holdings, Inc. on July 9, 2015. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: James C. Clemmer was appointed as a Class II director, effective immediately, with a term expiring at the 2017 annual meeting.
- Committee Assignment: Mr. Clemmer was appointed as an independent member of the Audit Committee. Consequently, David Burgstahler resigned from the Audit Committee.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. The document details the compensatory arrangements for the new director:
- Cash Fees: $50,000 annual board fee (prorated for 2015) and a $10,000 annual Audit Committee fee (prorated for 2015).
- Equity Grant: A one-time grant consisting of stock options and restricted common stock, each with an aggregate value of $50,000 based on the closing sales price prior to appointment.
- Vesting: All equity grants vest in three equal installments over the first three anniversaries of the grant date.
Key Facts for Investor Verification
- James C. Clemmer's prior role as President of the Medical Supplies segment at Covidien plc.
- The specific vesting schedule and grant price for the equity awards issued to Mr. Clemmer.
- The impact of the Board size increase on future governance decisions.
- Confirmation of David Burgstahler's continued status as a director following his resignation from the Audit Committee.